Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30442090 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL31418693 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL1412214 | 0.95 | TPSAB1 (0.50) | ALDH1A1TPSAB1TPSD1TPSG1LMNA | |
| SCHEMBL20785502 | 0.92 | ALDH1A1 (0.47) | ALDH1A1TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL19645166 | 0.84 | SMN1; SMN2 (0.40) | ALDH1A1TPSAB1TPSD1TPSG1LMNA | |
| SCHEMBL10703021 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL9044348 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CASP1 | |
| SCHEMBL12934822 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TPSAB1TPSD1TPSG1KDM1A | |
| SCHEMBL6420313 | 0.83 | GAA (0.58) | TPSAB1TPSD1TPSG1LMNASMN1; SMN2 | |
| SCHEMBL10633732 | 0.81 | CYP1A2 (0.52) | TPSAB1CASP1PRSS1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714956-A2 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12545716-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12503489-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-12-23 | — | — | US | disclosed |
| EP-3677589-B1 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-12280121-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12274754-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12268750-B2 | Immunoconjugates and methods | IMMUNOME, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240424124-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240424121-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240424123-A1 | IMMUNOCONJUGATES AND METHODS | ZENO MANAGEMENT, INC. | 2024-12-26 | — | — | US | disclosed |
| US-6436365-B2 | ADMINISTRATION VIA CATHETER OF RADIOACTIVE METAL COMPLEX TO SITE OF LEGION; TREATMENT OF ATHERSCLEROSIS; REDUCES UNDESIRED RADIOACTIVE EXPOSURE OF HEALTHY TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-10 | — | — | US | disclosed |
| EP-1011737-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-28 | — | — | EP | disclosed |
| CN-1254295-A | Surface-coated spring, method for the production thereof and use thereof for preventing restenosis | SCHERING AG (DE) | 2000-05-24 | — | — | CN | disclosed |
| EP-0979108-A2 | STENTS WITH A RADIOACTIVE SURFACE COATING, PROCESSES FOR PRODUCING THE SAME AND THEIR USE FOR RESTENOSIS PREVENTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999013920-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998048851-A2 | STENTS WITH A RADIOACTIVE SURFACE COATING | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-05 | — | — | WO | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0197478-A1 | Diphosphonic-acid derivatives, process for preparing them and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1986-10-15 | — | — | EP | disclosed |
| US-4388233-A | PROTEOLYTIC ENZYMES, FLUORIMETRIC ANALYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1983-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280121-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
| US-12545716-B2 | Immunoconjugates and methods | FCGR3B, FCGR2A, LY6K | ALDH1A1 1189/4885TPSAB1 1556/4885TPSD1 2404/4885 |
| US-20240424121-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | MKI67, FGF2, FGFR1 | ALDH1A1 1488/4885TPSAB1 627/4885TPSD1 2344/4885 |
| US-12503489-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | ALDH1A1 257/4885TPSAB1 1890/4885TPSD1 4713/4885 |
| US-12268750-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
| US-12274754-B2 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
| US-20240424124-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
| US-20240424123-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | ALDH1A1 120/4885TPSAB1 1906/4885TPSD1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.